


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on October 5, 2007.


Frank C. Eisenschenk, Ph.D., Patent Attorney

ELECTION UNDER 35 U.S.C. § 121
Examining Group 1647
Patent Application
Docket No. ARS-108
Serial No. 10/540,234

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Ian D. Dang
Art Unit : 1647
Applicants : Amanda Proudfoot, Maureen Ajuebor, Mark Swain
Serial No. : 10/540,234
Filed : June 21, 2005
Conf. No. : 1629
For : CC-Chemokine Mutants Against Liver Diseases

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

ELECTION UNDER 35 U.S.C. § 121

Sir:

In response to the written Restriction Requirement dated September 5, 2007 in the above-identified patent application, Applicants hereby elect CCL5/RANTES as the species and an autoimmune hepatitis as the species of liver disease, with traverse.

Prior to examination, Applicants respectfully request that the subject application be amended as follows: